To describe the events surrounding the recent termination of Elan Pharmaceutical's phase 2a trial of beta amyloid immunisation for Alzheimer's disease.
Conclusions:
Excessive and uncritical enthusiasm for new treatments can lead to negative clinical and financial outcomes.
